##plugins.themes.academic_pro.article.main##
Abstract
to study the possibilities of early prevention of CKD in patients with type 2 diabetes based on clinical and anamnestic data.
Keywords
anamnestic
possibilities
CKD
##plugins.themes.academic_pro.article.details##
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Kholikov A.Yu, Begmatov B.B, Urmanova Yu.M, & Narziev V.Sh. (2024). “Possibilities of early prevention of chronic kidney disease in patients with type 2 diabetes mellitus based on clinical and anamnestic data”. Texas Journal of Medical Science, 29, 43–50. https://doi.org/10.62480/tjms.2024.vol29.pp43-50
References
- Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 1997;157:1413–18.
- Fuller JH, Stevens LK, Wang SL, et al. Risk factors for cardiovascular mortality and morbidity: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(suppl 2):S54–64.
- Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225–32.
- de Boer IH, Rue TC, Hall YN. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305:2532–9.doi:10.1001/jama.2011.861
- Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014;370:1514-.doi:10.1056/NEJMoa1310799pmid:http://www.ncbi.nlm.nih.gov/pubmed/24738668
- Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14.doi:10.1016/j.diabres.2009.10.007
- Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol 2016;12:73-81.doi:10.1038/nrneph.2015.173
- Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 2020;98:S1-115.doi:10.1016/j.kint.2020.06.019pmid:http://www.ncbi.nlm.nih.gov/pubmed/32998798
- American Diabetes Association. 11. microvascular complications and foot care: standards of medical care in Diabetes-2021. Diabetes Care 2021;44:S151-67.doi:10.2337/dc21-S011pmid:http://www.ncbi.nlm.nih.gov/pubmed/33298422
- Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–89.doi:10.1056/NEJMoa0806470
- Schernthaner G, Schernthaner-Reiter MH. Therapy: risk of metformin use in patients with T2DM and advanced CKD. Nat Rev Endocrinol 2015;11:697-9.doi:10.1038/nrendo.2015.132pmid:http://www.ncbi.nlm.nih.gov/pubmed/26284445
- Kwon S, Kim YC, Park JY, et al. The long-term effects of metformin on patients with type 2 diabetic kidney disease. Diabetes Care 2020;43:948–55.doi:10.2337/dc19-0936pmid:http://www.ncbi.nlm.nih.gov/pubmed/32132005
- Roumie CL, Chipman J, Min JY, et al. Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function. JAMA 2019;322:1167-77.doi:10.1001/jama.2019.13206pmid:http://www.ncbi.nlm.nih.gov/pubmed/31536102
- Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010;170:1892-9.doi:10.1001/archinternmed.2010.409pmid:http://www.ncbi.nlm.nih.gov/pubmed/21098347
- Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-34.doi:10.1056/NEJMoa1515920
- Wanner C, Inzucchi SE, Zinman B, et al. Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: insights from the EMPA-REG outcome trial. Diabetes Obes Metab 2020;22:2335-47.doi:10.1111/dom.14158pmid:http://www.ncbi.nlm.nih.gov/pubmed/32744354
- Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-57.doi:10.1056/NEJMoa1812389pmid:http://www.ncbi.nlm.nih.gov/pubmed/30415602
- Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295-306.doi:10.1056/NEJMoa1811744